[Analysis of histological type and staging of cervical cancer as prognostic factors among women treated in the Department of Gynecology and Oncology, Jagiellonian University in the years 2001-2014].
Tomasz Basta, Iwona Gawron, Krzysztof Mirocki, Dorota Babczyk, Robert Jach
{"title":"[Analysis of histological type and staging of cervical cancer as prognostic factors among women treated in the Department of Gynecology and Oncology, Jagiellonian University in the years 2001-2014].","authors":"Tomasz Basta, Iwona Gawron, Krzysztof Mirocki, Dorota Babczyk, Robert Jach","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer (CC)\nis the fourth most common, in terms\nof incidence of new cases, cancer in\nwomen and the third leading cause of\ncancer deaths in women worldwide.\nSurvival of patients with CC depends\non many factors, including the type\nof cancer, grading, FIGO staging and\ntreatment.</p><p><strong>Material and methods: </strong>Analysis of survival of 524 patients diagnosed\nwith invasive and non-invasive CC depending\non histopathologic diagnosis,\nclinical staging, tumor grading and\ncombination of therapy.</p><p><strong>Results: </strong>The 2-fold increase in the\nrisk of death at diagnosis in order of\nHSIL> ca planoepitheliale> adenocarcinoma>\nsarcoma was noted. Grading\n2 and 3 significantly reduces the average\nsurvival in patients diagnosed with\nCC. The higher staging, the shorter the\naverage survival. Each pass by one\nFIGO stage was shown to increase\nthe risk of death by 46%. The risk of\ndeath increases by 4% with every year\nof woman’s life. The longest average\nsurvival, 72 months, characterized a\ngroup of women undergoing curettage,\nfollowed by radical hysterectomy/\ntrachelectomy and lymphadenectomy\nwithout adiuvant radio-/ chemotherapy.\nThe shortest survival, 26.9 months,\nwas observed in the group treated with\ncurettage followed by chemoradiation.</p><p><strong>Conclusions: </strong>Histopathology, clinical staging, grading, age and\ncombination of treatment proved to be\nsignificant factors affecting survival in\nwomen with CC.</p>","PeriodicalId":21148,"journal":{"name":"Przeglad lekarski","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przeglad lekarski","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Cervical cancer (CC)
is the fourth most common, in terms
of incidence of new cases, cancer in
women and the third leading cause of
cancer deaths in women worldwide.
Survival of patients with CC depends
on many factors, including the type
of cancer, grading, FIGO staging and
treatment.
Material and methods: Analysis of survival of 524 patients diagnosed
with invasive and non-invasive CC depending
on histopathologic diagnosis,
clinical staging, tumor grading and
combination of therapy.
Results: The 2-fold increase in the
risk of death at diagnosis in order of
HSIL> ca planoepitheliale> adenocarcinoma>
sarcoma was noted. Grading
2 and 3 significantly reduces the average
survival in patients diagnosed with
CC. The higher staging, the shorter the
average survival. Each pass by one
FIGO stage was shown to increase
the risk of death by 46%. The risk of
death increases by 4% with every year
of woman’s life. The longest average
survival, 72 months, characterized a
group of women undergoing curettage,
followed by radical hysterectomy/
trachelectomy and lymphadenectomy
without adiuvant radio-/ chemotherapy.
The shortest survival, 26.9 months,
was observed in the group treated with
curettage followed by chemoradiation.
Conclusions: Histopathology, clinical staging, grading, age and
combination of treatment proved to be
significant factors affecting survival in
women with CC.